Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.
Cell Metab. 2013.
PMID: 24206666
Free PMC article.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2024 | 0 |
Search Results
3 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.
Perry RJ, Kim T, Zhang XM, Lee HY, Pesta D, Popov VB, Zhang D, Rahimi Y, Jurczak MJ, Cline GW, Spiegel DA, Shulman GI.
Perry RJ, et al.
Cell Metab. 2013 Nov 5;18(5):740-8. doi: 10.1016/j.cmet.2013.10.004.
Cell Metab. 2013.
PMID: 24206666
Free PMC article.
Treatment with DNPME reversed hypertriglyceridemia, fatty liver, and whole-body insulin resistance in high-fat-fed rats and decreased hyperglycemia in a rat model of T2D with a wide therapeutic index. ...These results demonstrate that the …
Treatment with DNPME reversed hypertriglyceridemia, fatty liver, and whole-body insulin resistance …
Item in Clipboard
A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
Abulizi A, Perry RJ, Camporez JPG, Jurczak MJ, Petersen KF, Aspichueta P, Shulman GI.
Abulizi A, et al.
FASEB J. 2017 Jul;31(7):2916-2924. doi: 10.1096/fj.201700001R. Epub 2017 Mar 22.
FASEB J. 2017.
PMID: 28330852
Free PMC article.
CRMP treatment reversed hypertriglyceridemia and insulin resistance in liver and skeletal muscle. Reversal of insulin resistance could be attributed to reductions in diacylglycerol content and reduced PKC-epsilon and PKC-tet …
CRMP treatment reversed hypertriglyceridemia and insulin resistance in liver and skeletal muscle. Reve …
Item in Clipboard
Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.
Goedeke L, Peng L, Montalvo-Romeral V, Butrico GM, Dufour S, Zhang XM, Perry RJ, Cline GW, Kievit P, Chng K, Petersen KF, Shulman GI.
Goedeke L, et al.
Sci Transl Med. 2019 Oct 2;11(512):eaay0284. doi: 10.1126/scitranslmed.aay0284.
Sci Transl Med. 2019.
PMID: 31578240
Free PMC article.
Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one-third of the general population, and new therapies are urgently required. ...Here, we evaluated the impact of longer-term CRMP treatment on hepatic mitochondrial oxidation and on …
Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one-third of the general population, and new ther …
Item in Clipboard
Cite
Cite